CareDX Lab Solutions Inc. Allo Seq Tx17 Next Generation Sequencing (NGS) Reagent Kits

The National Institutes of Health (NIH) plans to issue a firm fixed-price purchase order to CareDx Lab Solutions Inc. for Next Generation Sequencing (NGS) reagent kits. The purpose of this acquisition is to secure a one-year supply of NGS reagents for the Human Leukocyte Antigen (HLA) Laboratory. The contract's performance period will run from January 16, 2026, to September 30, 2026. The required items include 80 units of ASTX.17 1(24)-RUO KIT and other related products. • The NIH is the leading federally funded biomedical research institution in the United States. • The HLA Laboratory within the Department of Transfusion Medicine at the Clinical Center provides clinical diagnostic laboratory testing, offers clinical consultations, maintains accreditation, engages in research, and supports and develops protocols. • The proposed vendor, CareDx Lab Solutions Inc., is the sole manufacturer of these NGS reagents. • Interested parties may identify their interest and capabilities in response to this posting.